Global Institute Of Stem Cell Therapy And Research

Archives

Author's Posts

-->

Liver Cirrhosis Treatment at GIOSTAR – Patient Testimonial

 

 

In April 2016, 55 years old, Mr. Ashwinbhai Soni, suffering with liver cirrhosis arrived at the GIOSTAR after quite sufferings and very concerned about his professional as well as personal life. His viral load was very high and liver enzymes were as well elevated beyond the limits, due to which his doctor suggested him of no other option; but a liver transplant. Read how Mr. Ashwinbhai Soni has undergone stem cell therapy with us and how is he feeling currently.

Hi my name is Ashwinbhai Soni and I am currently working with GV. Since last 4-5 years I had been regularly hospitalized for my weakness, abdominal pain, passing of blood through stool problems. Doctors had initially concluded a liver problem, but the severity of the issue was not noticed till the time, I consulted a gastroenterologist. He consulted me well and check for my personal, professional as well as family history. As per his suggestions, I underwent two-three diagnostic tests; which ultimately concluded a severe liver disease, named liver cirrhosis.

After that I had to be admitted 5-6 times in a hospital every year; for blood transfusions. I have even had blood vomits twice or thrice last year, I used to feel lot of weakness and my friends and family suggested me to take complete rest, considering severity of my issue. At one point of time, I was so frustrated that I was about to leave my job. I had been undergoing treatment at Sterling hospital with gastroenterologist, who ultimately suggested me liver transplant by analysing my biopsy reports. Luckily, through newspaper, I came to know about stem cells therapy at GIOSTAR and how many people have been benefitted without a surgery.

Doctors and specialists at GIOSTAR are very soft, knowledgeable; who made me understand the entire process, including risks and benefits. I finally decided to give a try; before opting for the liver transplant. I underwent total 4 cycles; although each cycle was just a daytime affair. The procedure was too smooth to my expectations; and I could internally feel the change, in the first sessions itself. However, my gastroenterologist was still suggesting me that a transplant is the better option; and this is not going to work.

After 2nd session, I found that my stamina is slowly increasing, along with my appetite and emotional mood swings. After 3rd sessions, I found out that I can work almost 10-12 hrs a day, whereas initially, I was not being able to continue even for 2 hrs. My appetite has considerably increased and I have started living normal life again. Even to my surprise even my gastroenterologist declared that I need not to undergo any transplant and everything is going on very smoothly. I may undergo additional sessions of stem cells therapy, as per expert’s advice; but for now I am very happy and thankful to all the staff of GIOSTAR; for bringing me back into my life.

Invitation from Journal of Clinical Research and Trial to Submit a Manuscript

Dear Anand S,

Greetings from Clinical Research and Trials (CRT) !

This is a special Request regarding manuscript contribution to our Journal. We will be glad if you can submit your manuscript along with cover letter at clinicaltrials@oatextjournals.com

We would like to inform you regarding our Annual Membership Program. Keeping in view your tremendous contribution to the scientific field, we wish to offer you free membership.

Kindly let us know your opinion in this regard. So, that we will send you more details regarding individual membership and other benefits.

Awaiting for your positive response.

Have a great day

Best Regards
Regina Mathew
Editorial Coordinator
Office Gold, building 3 Chiswick Park
Greater London, W4 5YA
United Kingdom

FDA-Approved Study Uses Adipose Stem Cells for Treatment of Shoulder Injuries

 

Sanford Health is conducting the first clinical trial approved by the FDA to treat injured shoulders using patients’ adipose stem cells.

“A number of studies have demonstrated that fat-derived stem cells have great healing potential by boosting the immune system and helping the natural healing process,” Jason Hurd, MD, a principal investigator of the study and orthopedic surgeon at Sanford Orthopedics & Sports Medicine in Sioux Falls, South Dakota, told Orthopedics Today. “Also, isolation of fat tissue is less invasive than isolation of other pools of stem cells, such as those found in the bone marrow, which might include a more complicated surgical procedure.”

Hurd and Mark Lundeen, MD, the other lead investigator of the study, began the trial in December to determine whether adipose stem cells, extracted from a patient’s abdominal fat, could repair partial thickness tears in the rotator cuff, according to a press release from Sanford Health. Investigators hypothesize that injecting the stem cells into the injured area could activate the patient’s body’s natural healing process, accelerate healing and regenerate tissue.

“Sanford Health physicians and scientists are the first in the country to work with the FDA on a trial using adipose stem cells in rotator cuff tears, which are common,” Kelby Krabbenhoft, president and chief executive officer of Sanford Health, said in the release. “We have been monitoring the potential of these types of stem cells for some time. In Europe, adipose stem cells have been used as a therapy option for damaged tissues and are approved to carry the CE mark, which signifies that a product has been assessed by and meets certain safety, health and environmental protection requirements in the European Union.” ‒ by Monica Jaramillo

Source : https://goo.gl/VLSG84

Tackling Parkinson Disease Through Cell Rejuvenation

 

It started with a hand tremor that was more pronounced when typing. At first, it just interfered with hobbies. But it got progressively worse. Soon handwriting was illegible. The simple act of walking became difficult. Memory problems and an urgency to urinate finally send the patient to the doctor, for the cruel diagnosis: Parkinson disease, a condition resulting from cell degeneration in the brain.

There are other disorders like it, Alzheimer for example, that share an important trait — they arise when the body’s aging cells stop doing what they are supposed to do.

For many of these conditions, there are no cures, just treatments designed to slow the progression, where possible. But we may soon be looking at new treatment options developed through mitochondrial genetics and the study of aging.

The degeneration of aging cells is related to abnormalities in power plant organelles called mitochondria. In normal cell function, these mitochondria deteriorate over time and are eventually ejected from the cell.

Over the past few decades, researchers have discovered evidence that mitochondria become dysfunctional because of mutations in their DNA. (Mitochondrial DNA, or mtDNA, is separate from the DNA comprising the chromosomes of a cell’s nucleus.) The dysfunction, in turn, is connected to cellular aging and the onset of degenerative diseases. There are two new developments in this area of research.

Tackling Parkinson Disease Through Cell Rejuvenation

The first involves the realization that while certain mtDNA mutations contribute to the disruption of mitochondrial function, there are mutations in other mitochondrial genes that prevent the cell from removing the dysfunctional mitochondria. Essentially, the cell loses the ability to perform its own quality control.

“We know that increased rates of mtDNA mutation cause premature aging,” said Bruce Hay, Professor of biology and biological engineering at the California Institute of Technology. “This, coupled with the fact that mutant mtDNA accumulates in key tissues such as neurons and muscle that lose function as we age, suggests that if we could reduce the amount of mutant mtDNA, we could slow or reverse important aspects of aging.”

This brings us to the second major development relevant to mitochondria in disease — that genetic technology is now at a point where the targeted removal of the problem mitochondrial genes can become the basis for clinical intervention. This is the implication of research that Hay and colleagues both at Caltech and the University of California at Los Angeles have described in a paper published recently in the prestigious journal Nature Communications.

Fixing body tissues by knocking out genes that prevent bad mitochondrial from being ousted in a timely fashion might sound like science fiction, but that’s where things are going and it’s part of a growing trend of what’s being described as mitochondrial medicine.

With degenerative diseases, the standard treatment involves the replacement of the physiologic function of the diseased tissue. In Parkinson disease, this often means replacing a neurotransmitter called dopamine in a part of the brain where it’s lacking, due to degeneration of dopamine-making cells. While this works well in the initial stages of the disease, it gradually becomes less effective.

There are two new strategies. One is to regenerate the failing tissue using stem cells. The other is gene therapy in which the patients’ own brain cells are given the ability to make something they don’t usually make. For instance, the part of the brain that usually receives dopamine is given the ability to make its own dopamine.

Neurosurgeons are actually quite good at injecting agents into specific regions of the brain with extreme precision. This is why gene therapy and stem cell therapy are showing promise. But this also means there’s a capability to deliver agents that could affect mitochondria. It means that it should be possible in the near future to manage degenerative diseases with a third advance treatment prong: restoring the cell’s ability to expel failing mitochondria.

Source : https://goo.gl/JdfS9M

Stem Cell Revolution Trudges Forward

We are still in the early stages [of stem cell treatment]. In 2014, Dr. Masayo Takahashi and her colleagues at the Riken Center for Developmental Biology had great success using iPS cells to treat macular degeneration.

In some ways, yes, [the promise of stem cells] is overstated. For example, target diseases for cell therapy are limited. There are about 10: Parkinson’s, retinal and corneal diseases, heart and liver failure, diabetes and only a few more — spinal cord injury, joint disorders and some blood disorders…The number of human diseases is enormous.

Stem Cell Revolution Trudges Forward

I think the science has moved too far ahead of talk of ethical issues. When we succeeded in making iPS cells, we thought, wow, we can now overcome ethical issues of using embryos to make stem cell lines.

But soon after, we realized we are making new ethical issues. We can make a human kidney or human pancreas in pigs if human iPS cells are injected into the embryo. But how much can we do those things?

It is very controversial. These treatments may help thousands of people. So getting an ethical consensus is extremely important.

Source : https://goo.gl/1tIykZ

Make An Enquiry

We are here to help you

WordPress Video Lightbox